5 AI Stocks to Own for the Inference Age

The article argues that AI inference is emerging as the next major wave after LLM training, favoring Nvidia, AMD, Broadcom, Cerebras, and Micron. It highlights Nvidia's end-to-end inference racks, AMD's memory-heavy chiplet advantages and large purchase commitments, Cerebras' 15x faster inference chips with more than $20 billion in reported OpenAI commitments, Broadcom's expected custom-chip sales above $100 billion by fiscal 2027, and Micron's HBM benefit from rising memory demand. Overall, the piece is constructive on the AI hardware stack, but it is primarily long-form stock commentary rather than a company-specific catalyst.

Analysis

The key second-order shift is that inference commoditizes raw FLOPS and re-rates value toward memory density, software integration, and system-level power efficiency. That favors names with strong HBM access and rack-level control, while it pressures any GPU vendor that depends on being the default compute layer rather than the orchestrator of the whole stack. In practice, the winners are likely to be the companies that can monetize both the silicon and the surrounding platform, while the losers are undifferentiated accelerators that lack software lock-in or memory advantage.

Broadcom looks best positioned on a risk-adjusted basis because custom silicon scales with hyperscaler capex without requiring the market to choose a single winner. The more inference budgets migrate in-house, the more Broadcom becomes the toll collector on bespoke AI infrastructure, and that has better durability than a pure product-cycle trade. AMD has upside, but the market may be underestimating how much of the benefit depends on execution in software adoption and on whether customers diversify away from the incumbent rather than merely dual-source.

Micron is the clearest operating leverage story: inference increases the mix of memory per dollar of compute, so HBM tightness can persist even if unit growth slows. The risk is that the current pricing cycle invites supply response from Korea faster than investors expect, which could flatten margins in 2-3 quarters even if AI demand remains strong. Cerebras is the most interesting speculative exposure, but its economics remain hostage to deployment complexity; a few large commitments do not yet prove repeatable market share gains.

The contrarian takeaway is that the market may be overpricing the idea that inference automatically broadens the winner set. If hyperscalers successfully standardize around a smaller number of custom architectures, the value accrues upstream to system integrators and memory suppliers, not necessarily to every chip vendor with an AI narrative. Conversely, if agentic workloads prove more CPU-heavy than expected, the real embedded beneficiary may be a less obvious infrastructure basket rather than the headline AI accelerators.

Key Decisions for Investors

• Overweight AVGO on a 6-12 month view; best risk/reward for inference monetization because custom chip design wins compound with hyperscaler spend and are less exposed to a single product cycle.
• Maintain a tactical long MU, but treat it as a cycle trade rather than a secular compounder; target 3-6 months of elevated pricing strength, then reassess if DRAM supply response accelerates.
• Pair long AVGO / short AMD for the next 2-4 quarters: expresses the view that custom silicon and design services capture more durable inference spend than a close second-source GPU supplier.
• If seeking higher beta, buy NVDA pullbacks rather than momentum-chasing; the key support is software control, but near-term upside is likely capped unless it converts inference racks into a dominant platform standard.
• Avoid chasing CBRS as a core position; only consider a small call-spread style exposure if there is evidence of repeatable enterprise adoption, since the risk/reward remains skewed to a niche outcome.